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Abstract
Studies so far indicate that reduced intensity
transplantation (RIT) may have an important
role in treating patients with primary immunod-
eficiency disease (PID). Unlike more standard
approaches, such regimens can be used without
severe  toxicity  in  patients  with  severe  pul-
monary or hepatic disease. RIT also offers the
advantage that long-term sequelae such as in-
fertility or growth retardation may be avoided or
reduced. RIT appears to be most appropriate for
those patients with significant co-morbidities
(eg T cell deficiencies) and those undergoing
unrelated donor haematopoietic cell transplan-
tation. More studies are required using phar-
macokinetic  monitoring  (eg  busulphan,  treo-
sulfan and alemtuzumab) and varying stem cell
sources to optimise graft vs marrow reactions
and minimise graft vs host disease. In certain
PID patients RIT will be the “first step” towards
establishing donor cell engraftment; second in-
fusions of donor stem cells, donor lymphocyte
infusions,  or  a  second  myeloablative  HCT,
which appears to be well tolerated, may be re-
quired in some patients with low level donor
chimerism or graft rejection.
Introduction
Many  children  with  primary  immunodefi-
ciency disease (PID) have significant co-mor-
bidities at the time of haematopoietic cell trans-
plantation (HCT) and conventional myeloabla-
tive preparation may be associated with signifi-
cant treatment-related toxicity as well as long-
term sequelae. Over the past decade reduced in-
tensity transplantation (RIT) has become a well
established approach in adult patients with ma-
lignant  disease,  extending  curative  HCT  to
older individuals and patients with co-morbidi-
ties otherwise ineligible for myeloablative pro-
cedures.1,2,3RIT is therefore an attractive option
for children with PID, and particularly as there
is no requirement for high dose chemotherapy
to eradicate malignancy; graft failure, however,
may be a concern in certain groups as many pa-
tients  with  non-malignant  disorders  will  not
have received prior chemotherapy.
Mechanism of RIT
Conventional HCT prevents rejection by the
use  of  supralethal  chemotherapy  to  remove
host-versus-graft (HvG) reactions, and create
marrow  space,  often  achieving  full  donor
chimerism in the early months post HCT. RIT
prevents rejection by the use of pre +/- post
HCT immunosuppression to achieve tolerance
and a graft-versus-marrow (GvM) reaction to
create  space.  In  this  setting  a  stable  mixed
chimerism  is  often  achieved  which  may  be
converted to full donor chimerism, if required,
by tailing immunosuppression or donor lym-
phocyte infusions (DLI). Unlike the situation
in malignant disease, stable mixed chimerism
in the affected cell lineage is usually sufficient
to cure genetic diseases.
Two general approaches have been used to
develop RIT regimens.4,5
So-called  reduced  intensity conditioning
(RIC) protocols (Figure 1) have been developed
by replacing myeloablative agents with more
immunosuppressive and less myelosuppressive
properties.6,7 Such protocols, nevertheless, still
contain agents capable of ablating stem cells eg
busulphan or melphalan, but at a reduced dose
compared to conventional HCT. In contrast, reg-
imens with minimal toxicity or minimal inten-
sity conditioning  (MIC)  (Figure  1)  are  truly
non-myeloablative and contain only immuno-
suppressive agents. These latter regimens, de-
veloped in animal models, initially used irradi-
ation to induce a degree of immunosuppres-
sion pre-transplant, followed by post-transplant
immunosuppression given to control residual
host as well as newly infused donor, alloreac-
tive T cells.8 By definition MIC procedures have
been  associated  with  less  toxicity  than  RIC
HCT, however, as MIC relies solely on a GvM re-
action to make marrow space, there is a sug-
gestion that MIC HCT may be associated with
an  increased  incidence  of  graft-versus-host-
disease (GvHD), particularly chronic (c)GvHD,
and especially in the unrelated donor setting.
RIT protocols for PID
Most reduced and minimal intensity proto-
cols are based around the purine analogue flu-
darabine which has profound immunosuppres-
sive properties (Figure 1). RIC protocols com-
bine fludarabine with a marrow ablative agent
either melphalan, busulphan or treosulphan,
and MIC protocols combine fludarabine with





Our group recently updated their series, re-
porting 113 patients with PID who had under-
gone RIT between 1998 and 2006.9 The ma-
jority of patients (93/113) received a RIC reg-
imen  consisting  of  Campath  1H  1  mg/kg
(Alemtuzumab), fludarabine 150 mg/m2, mel-
phalan  140  mg/m2 (FMC-RIC).  At  a  median
follow-up of 2.9 years (range 2 months to 8
years) the overall survival (OS) for these pa-
tients was 82% (93/113) and 91/133 (81%) had
stable donor engraftment. The survival curve
following RIC HCT for the major PID diseases
compared to that following MAC HCT in other
European centers is shown in Figure 2.
Long-term chimerism (median follow-up 4.6
years, range 6 months to 10.6 years) has also
been examined in 118 children with PID re-
ceiving FMC-RIC HCT in London [Rao et al.
2010  manuscript  in  preparation].  After  pro-
longed  follow-up  donor  chimerism  was  low
(<50%) in 24/118 (20%) patients, 5 patients
have required a second myeloablative (MAC)
HCT, one required a CD34+ cell top-up, two pa-
tients were given DLI, one patient with WAS
underwent a splenectomy. Twenty one of these
24 patients are currently alive and well with
stable  engraftment.  Two  patients  have  died,
one following 2nd HCT and one from progres-
sive disease, and one patient has continuing
poor  immune  reconstitution.  Almost  all  pa-
tients developing low level donor chimerism
received BM rather than PBPCs as stem cell
source and MSD and MFD had more low MC
than MUDs and mMUDs (30% and 28% vs 18%
and 11%). Very low (<10%) donor chimerism
was almost entirely limited to the myeloid se-
ries. Cyclosporin withdrawal appeared to have a
positive effect on lymphoid chimerism but not
on myeloid engraftment. Lymphoid chimerism
changed little after the first year but myeloid
chimerism did decrease further after one year
in  a  few  patients.  Consequently  5  years  fol-
lowing RIC HCT for PID just under 10% of pa-
tients have required a second procedure.
Shenoy and colleagues10 used FMC-RIC HCT
in 16 patients with non-malignant disorders
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including 2 PID patients, but in their series ad-
ministered Campath 1H 33 or 48 mg total dose
early pre HCT from day -21 to day -19. All four-
teen evaluable patients had complete or high
level (> 50%) donor chimerism in all lineages,
suggesting that lower doses or administration
of Campath 1H away from the graft may in-
crease donor chimerism in the HLA-matched
setting. Further studies are underway to ex-
amine  whether  Campath  levels  taken  on  or
around day zero may predict graft outcome in
these  patients:  ie  high  levels  predicting  for
slow  immune  reconstitution  and  viral  infec-
tions and low levels for GVHD and complete
donor  chimerism.  These  results  may  better
help to define the optimal method of delivering
Campath in the RIT setting.
The benefit from FMC-RIC HCT was most
evident  in  children  over  1  year  of  age.  For
SCID  patients  under  1  year,  TRM  remained
high even with RIC HCT (24% in the London
series) with 17/30 patients (57%) needing in-
tensive care management post HCT; this com-
pares to 26/118 (22%) in the group > 1 yr of
age (P<0.0001).
Fludarabine/busulphan
The most notable study exploring RIC HCT
in  PID  using  fludarabine  and  low  dose
busulfan has been reported in chronic granulo-
matous disease (CGD) patients. Intravenous
busulfan 8-10 mg/kg (adjusted with busulphan
kinetics in pediatric patients), fludarabine 180
mg/m2 and  ATG  40  mg/kg  was  used  with
matched donors (MSD=5, MUD=3) in 8 high-
risk CGD patients and led to 90-100% donor
chimerism in all cases at a median follow-up of
26 months.11,12 This is despite the use of BM in
7/8 cases. Seven patients were alive and well
and all active inflammatory and infectious foci
were  cured.  One  adult  patient  who  had  re-
ceived PBSC from a CMV negative MUD died
on day +150 of CMV pneumonitis. This cohort
has recently been updated and 27/28 CGD pa-
tients survive following RIT HCT with MSD(14)




fonate)  is  the  pro-drug  of  L-epoxybutane,  a
water  soluble  bifunctional  alkylating  agent
with  myeloablative  and  immunosuppressive
properties and has been shown to provide ef-
fective HCT conditioning with reduced risk of
toxicities, particularly veno-occlusive disease
(VOD), when compared to busulfan.13Two cen-
ters in the UK have recently examined the out-
come in 70 children with PID undergoing HCT
with treosulfan based regimens.14 Children re-
ceived 42 g/m2 or 36 g/m2 of treosulfan with cy-
clophosphamide 200 mg/kg (30) or fludarabine
150 mg/m2 (40), with alemtuzumab in most.
Median age at transplant was 8.5 months (1.2
to  175);  forty-six  (66%)  patients  were  12
months or younger. Overall survival was 81%,
and equivalent in those aged less or greater
than one year. The combination of treosulfan
with  fludarabine  was  associated  with  lower
toxicity and improved T cell chimerism. There
were significantly fewer under 1 year olds ad-
mitted to intensive care following HCT in this
study (12/44) compared to those who received
the combination of fludarabine and melphalan
(17/30 P=0.0155).
Long-term  follow  up  is  required  to  deter-
mine gonadotoxic effects, but the combination
Article
Figure 1. A hierarchy of commonly used minimal intensity (MIC), reduced intensity (RIC)
and myeloablative conditioning (MAC) regimens in PID patients; Gy, gray; Flu, fludara-
bine; cyclo, cyclophosphamide; BU8, busulfan 8 mg/kg; BU14-16, busulfan 14-16 mg/kg;
CY120-200, cyclophosphamide 120-200 mg/kg; DLI, donor lymphocyte infusion; ATG,
antithymocyte globulin. Bone Marrow Transplant 2008;41(2):174, with permission.
GOSH-RIC, Great Ormond Street Hospital reduced intensity conditioning HCT. 
Europe MAC, myeloablative HCT performed in European centres. Def, deficiency.
Figure 2. Improvement in outcome of stem cell transplantation for T-cell immune defi-
ciency.of fludarabine with treosulfan is a good choice
of conditioning for HCT in PID of any age.
Minimal intensity conditioning
Fludarabine/low dose TBI
The Seattle group investigated a MIC reg-
imen  in  14  patients  (12  children  and  2
adults) with PID and coexisting infections,
organ  toxicity  or  other  factors  precluding
conventional HCT.15 The majority of patients
received 200 cGy TBI plus Flu (30 mg/m2 per
day; x3 days -4 to -2) as conditioning and all
patients  received  HLA-matched  grafts  with
intensive  post-graft  immunosuppression
with  CsA/MMF.  No  serotherapy  was  given.
Thirteen  patients  established  mixed  (n=5)
or full (n=8) donor chimerism and one re-
jected the graft. OS at 3 years was 62% with a
TRM of 23%. Eight of ten evaluable patients
had  correction  of  immune  deficiency  with
stable  donor  engraftment.  However,  there
was a high rate of GVHD with 11/14 devel-
oping  significant  aGVHD  (mostly  grade  II)
and extensive cGVHD in eight patients, re-
flecting both the use of peripheral blood as
the  stem  cell  source  and  the  absence  of
serotherapy.  This  approach  was  associated
with a lower incidence of viral infections/re-
activations, notably EBV, than RIC regimens
utilizing serotherapy, however, the high inci-
dence of cGVHD would be a significant ob-
stacle to broader use of this regimen in chil-
dren with non-malignant disorders.
Fludarabine/cyclophosphamide/mabs
Our group has explored a MIC protocol com-
bining fludarabine (30 mg/m2 x 5 day -8 to -4)
and low dose cyclophosphamide (300 mg/m2 x
4 on day -7 to -4) with two rat anti-C45 mono-
clonal antibodies YTH 24.5/YTH 54.12 for addi-
tional myelosuppression, and serotherapy with
Campath 1H either 0.6 mg/kg or 0.3 mg/kg with
UD  or  MSD  respectively.16 Patients  were  at
particularly high risk from HCT related toxicity
even with RIC protocols due to severe pre-ex-
isting organ toxicity, age < 1 year, or the pres-
ence of DNA/telomere repair disorders. In total
16  patients  underwent  MIC  HCT  from  MSD
(5), MUD (9) and mMUD (2). Conditioning
was well tolerated with only 2 cases of grade 3
and no grade 4 toxicity. Six out of 16 patients
(38%) developed significant aGVHD (3 grade II
skin and 3 grade III skin/gut). Five of 16 pa-
tients (31%) developed cGVHD (limited in 3
and extensive in 2) which has resolved in all
cases. Of note, the incidence of GVHD was re-
duced when BM was used as stem cell source
(2/10 BM recipients compared with 4/4 evalu-
able  PBSC  recipients  developed  aGVHD  >
grade  II).  Similarly  the  incidence  of  cGVHD
was lower in recipients of BM (2/10) as com-
pared to PBSC (3/4). At a median of 9.5 days
(range 1-15), 16/16 patients had a neutrophil
count > 0.5x109/L. One patient failed to engraft
and had autologous recovery and one patient
who received a mismatched CB engrafted with
stable mixed chimerism after a very extended
period. Donor chimerism was 100% in 
3⁄4 PBSC
recipients with one PBSC recipient rejecting
the  graft.  Three  out  of  10  BM  recipients
achieved 100% donor chimerism, 3 achieved
stable high level MC in both mononuclear and
granulocyte lineages and 3 achieved donor T
cell  chimerism  without  susutained  myeloid
chimerism. One achieved very low level donor
chimerism and required a second SCT. At a
median of 37 months post HCT 13/16 patients
in this high risk cohort were alive and cured
from their underlying disease. In terms of OS,
SCID patients < 1 year of age appeared to gain
particular benefit from this MIC HCT protocol
(Figure 3).
Stem cell source
The balance of HvG and GvH/GvM reflects
the complex interactions of stem cell source
with  disease  type,  conditioning  regimen,
serotherapy, graft content (CD34+, CD3+, NK-
KIR alloreactivity) and GvHD prophylaxis, and
is more finely balanced in RIT than MAC HCT.
Early  warning  of  impending  graft  rejection
may  be  gained  from  recipient  chimerism
status  in  NK-cells  on  day  +2817 or  early  in-
creasing  MC  >  30%  host  cells,18 and  might
prompt timely intervention by withdrawl of im-
mune suppression or DLI.
In contrast to reports in adults, treatment-
related mortality, treatment failure, and mor-
tality were higher after MAC transplantation in
children using PBPCs as opposed to BM.19 Fol-
lowing RIT, the use of PBSCs appears to be as-
sociated  with  improved  donor  chimerism  in
recipents with PID,14,15 but at the cost of in-
creased rates of GvHD, particularly in mMUD;
in London PBPCs are advocated for 10/10 HLA
matched  related  and  unrelated  donors  fol-
lowing RIT HCT and new approaches are being
pursued for mMUDs (Rao et al., 2010 manu-
script in preparation). In the UK, the use of
GCSF is not advocated in sibling donors <16
yrs of age, and as the combination of RIT and
MSD  BM  often  leads  to  low  level  donor
chimerism in PID patients, MAC is generally
preferred for this group.
There has been increasing interest in the
use of UCB in PID but using largely myeloabla-
tive preparations.20 UCB has the advantage of
immediate access and a lower rate of GvHD
making  it  particularly  attractive  stem  cell
source for children with PID. There is limited
experience with the use of RIT and UCB in
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Figure 3. Comparison of disease-free survival of SCID patients < 1 year of age transplant-
ed  using  anti-CD45  MAb-based  MIC,  fludarabine/melphalan  based  RIC  and  bu  sul  -
phan/cyclophosphamide conditioning. Reproduced with permission. Kaplan-Meier curves
showing disease-free survival (days) of SCID patients age < 1 year conditioned with (1)
CD45 MAb-based MIC regimen (n = 8, DFS 100%) (2) fludarabine/melphalan-based RIC
regimen (n = 21, DFS 71.4%) and (3) busulphan/cyclophosphamide-based conditioning
(n= 31, DFS 77.4%). The cohort conditioned with CD45-based MIC was transplanted
between 2003-2007 (donor source 63% MUD, 25% MMUD, 13% MSD, 37% Bneg phe-
notype), the cohort conditioned with fludarabine/melphalan was transplanted between
1999-2003 (donor source 81% MUD, 19% MMUD, 57% Bneg phenotype) and the cohort
transplanted  with  busulphan/cyclophosphamide  was  transplanted  between  2003-2005
(donor source 57% MUD, 30% MSD, 13% MFD, 46% Bneg phenotype).16
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had  treosulfan  based  RIC  HCT  in  UK  sur-
vived;14 the  omission  of  serotherapy  in  this
group led to high levels of donor chimerism
and rapid reconstitution of CD4+ lymphocytes
and anti-viral immunity within 1-2 months of
HCT,  making  this  combination  particularly
suitable for PID.
Conclusions
RIT has an important role in treating pa-
tients with PID, and appears to be most appro-
priate for those patients with significant co-
morbidities (eg T cell deficiencies) and those
undergoing UD HCT; the optimal choice of pro-
tocol and stem cell source remains to be eluci-
dated. RIT also offers the advantage that long-
term sequelae such as infertility or growth re-
tardation may be avoided or reduced. In certain
PID  patients  RIT  will  be  the  “first  step”  to-
wards  establishing  donor  cell  engraftment,
second  infusions  of  donor  stem  cells,  donor
lymphocyte infusions, or a second myeloabla-
tive HCT may be required.
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